Axcella Health, Inc. (AXLA)

NASDAQ: AXLA · Delayed Price · USD
1.70
0.10 (6.25%)
At close: May 19, 2022 4:00 PM
1.71
0.01 (0.59%)
After-hours:May 19, 2022 4:15 PM EDT
Market Cap89.38M
Revenue (ttm)n/a
Net Income (ttm)-68.48M
Shares Out52.58M
EPS (ttm)-1.70
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume11,657
Open1.72
Previous Close1.60
Day's Range1.60 - 1.72
52-Week Range1.35 - 5.90
Beta1.39
AnalystsBuy
Price Target11.73 (+590.0%)
Earnings DateMay 5, 2022

About AXLA

Axcella Health Inc. operates as a clinical stage biotechnology company in the United States. The company treats complex diseases and enhances health using endogenous metabolic modulator compositions. Its lead product candidates include AXA1665, which is in Phase 2 clinical trial for the reduction in risk of overt hepatic encephalopathy recurrence; and AXA1125 that is in Phase 2b clinical trial for treating non-alcoholic steatohepatitis, as well as in Phase 2a clinical trial for Long COVID therapy for patients. The company was formerly known as ...

IndustryBiotechnology
IPO DateMay 9, 2019
Employees59
Stock ExchangeNASDAQ
Ticker SymbolAXLA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 13 analysts, the average rating for AXLA stock is "Buy." The 12-month stock price forecast is 11.73, which is an increase of 590.00% from the latest price.

Price Target
$11.73
(590.00% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Axcella Therapeutics to Participate in the H.C. Wainwright Global Investment Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabol...

12 hours ago - Business Wire

Axcella Reports First Quarter Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogenous metabol...

2 weeks ago - Business Wire

Axcella Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

1 month ago - Business Wire

Axcella to Report Fourth Quarter and Year End 2021 Financial Results on March 30, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

1 month ago - Business Wire

Insiders Buy Over $7M Of 3 Penny Stocks

The US Federal Reserve, on Wednesday, raised its target fed funds rate by 0.25%, its first interest rate hike since 2018. Investors, meanwhile, focused on some notable insider trades When insiders purch...

Other symbols:DMMMLP
2 months ago - Benzinga

Axcella Therapeutics Announces $25 Million Registered Direct Offering of Common Stock Priced At The Market

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

2 months ago - Business Wire

Axcella Therapeutics Announces FDA Fast Track Designation for AXA1125 in NASH

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

3 months ago - Business Wire

Axcella Therapeutics to Participate in the SVB Leerink Global Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

3 months ago - Business Wire

Axcella Therapeutics Announces Appointment of New Chief Financial Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

3 months ago - Business Wire

Axcella Health Inc. (AXLA) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now

Axcella Health Inc. (AXLA) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could ...

3 months ago - Zacks Investment Research

Axcella Therapeutics Details Clinical and Operational Milestones for 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

4 months ago - Business Wire

Axcella Therapeutics to Present at the H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

4 months ago - Business Wire

Down 24% in 4 Weeks, Here's Why Axcella Health Inc. (AXLA) Looks Ripe for a Turnaround

The heavy selling pressure might have exhausted for Axcella Health Inc. (AXLA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street a...

4 months ago - Zacks Investment Research

Axcella Kickstarts Long COVID Phase 2 Clinical Trial

Axcella Therapeutics Inc (NASDAQ: AXLA) has started patient screening in a Phase 2a trial of AXA1125, an oral product candidate, as a potential treatment for Long COVID. Phase 2a evaluates the efficacy ...

5 months ago - Benzinga

Axcella Therapeutics Announces Initiation of AXA1125 Long COVID Phase 2a Clinical Trial

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

5 months ago - Business Wire

Down 24.3% in 4 Weeks, Here's Why You Should You Buy the Dip in Axcella Health Inc. (AXLA)

Axcella Health Inc. (AXLA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in ...

5 months ago - Zacks Investment Research

Axcella Therapeutics Promotes Margaret Koziel, M.D., to Chief Medical Officer

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

5 months ago - Business Wire

Axcella Therapeutics to Participate in Piper Sandler 33rd Annual Healthcare Conference

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA #EMMs--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted en...

6 months ago - Business Wire

5 Winning Stocks Backed by the Overlooked Rising P/E Ratio

Want to try an out-of-the-box approach? Tap five stocks, namely OMI, STKL, CASY, LAZY and AXLA, with increasing P/E ratios.

Other symbols:CASYLAZYOMISTKL
6 months ago - Zacks Investment Research

Is a Surprise Coming for Axcella Health (AXLA) This Earnings Season?

Axcella Health (AXLA) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

6 months ago - Zacks Investment Research

Axcella Therapeutics Reports Third Quarter Financial Results and Provides Update on Long COVID, OHE and NASH Clinical...

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

6 months ago - Business Wire

Axcella Therapeutics Announces Upcoming Presentations at AASLD's The Liver Meeting® 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-targeted endogeno...

6 months ago - Business Wire

Axcella To Test NASH Candidate In Long COVID Patients

Axcella Health Inc (NASDAQ: AXLA) has announced a new clinical program investigating AXA1125 as a potential treatment for patients with Long COVID. Symptoms last for months following recovery from the i...

6 months ago - Benzinga

Axcella Therapeutics Launches Clinical Program to Develop Treatment for Patients with Long COVID

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA #LongCOVID--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using multi-target...

6 months ago - Business Wire

Axcella, Now Axcella Therapeutics, to Host Virtual R&D Day on October 26, 2021

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AXLA--Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology company pioneering a new approach to treat complex diseases using endogenous metabolic mo...

7 months ago - Business Wire